Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-392]
 ACTION: Notice of application.
 DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 22, 2015.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA 
                        **Federal Register**
                         Representative/ODXL, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on July 3, 2014, Cody Laboratories, Inc., Steve Hartman—Vice President of Compliance, 601 Yellowstone Avenue, Cody, Wyoming 82414 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled substance
ScheduleDihydromorphine (9145)
IAmphetamine (1100)
IIMethamphetamine (1105)
IIAmobarbital (2125)
IIPentobarbital (2270)
IISecobarbital (2315)
II4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333)
IIPhenylacetone (8501)
II( print page 22561)Cocaine (9041)
IICodeine (9050)
IIDihydrocodeine (9120)
IIOxycodone (9143)
IIHydromorphone (9150)
IIDiphenoxylate (9170)
IIEcgonine (9180)
IIHydrocodone (9193)
IIMeperidine (9230)
IIMethadone (9250)
IIMorphine (9300)
IIThebaine (9333)
IIOxymorphone (9652)
IIAlfentanil (9737)
IIRemifentanil (9739)
IISufentanil (9740)
IIFentanyl (9801)
II
 The company plans to manufacture the listed controlled substances in bulk for sale to its customers. Dated: April 14, 2015. Joseph T. Rannazzisi, Deputy Assistant Administrator.


[FR Doc. 2015-09326 Filed 4-21-15; 8:45 am] BILLING CODE 4410-09-P